Evidence map›Paper›PMID 40281066›Full record

ArticleScientific reports2025

25(OH)D3 and F-25(OH)D as indicators of chronic kidney disease progression in patients with rheumatoid arthritis.

Jie Tang, Lijuan Wu, Bei Xu, Wenqiang Jiang, Yan Wu, Jinmei Zou, Wenbing Deng, Yuwei Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jie Tang *Department of Clinical Blood Transfusion Laboratory, School of Medicine, Mianyang Central Hospital, University of Electronic Science and Technology of China, Mianyang, 621000, PR China.
Lijuan Wu *Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, 610041, PR China.
Bei XuDepartment of Clinical Laboratory, School of Medicine, Mianyang Central Hospital, University of Electronic Science and Technology of China, Mianyang, 621000, PR China.
Wenqiang JiangDepartment of Clinical Laboratory, School of Medicine, Mianyang Central Hospital, University of Electronic Science and Technology of China, Mianyang, 621000, PR China.
Yan WuDepartment of Clinical Laboratory, School of Medicine, Mianyang Central Hospital, University of Electronic Science and Technology of China, Mianyang, 621000, PR China.
Jinmei ZouDepartment of Rheumatology and Immunology, School of Medicine, Mianyang Central Hospital, University of Electronic Science and Technology of China, Mianyang, 621000, PR China.
Wenbing DengDepartment of Clinical Blood Transfusion Laboratory, School of Medicine, Mianyang Central Hospital, University of Electronic Science and Technology of China, Mianyang, 621000, PR China. myzxyysxk@163.com.
Yuwei YangDepartment of Clinical Laboratory, School of Medicine, Mianyang Central Hospital, University of Electronic Science and Technology of China, Mianyang, 621000, PR China. yyw318@sc-mch.cn.

Funding

the Basic Application Project of Science & Technology Department of Sichuan Province 2019YJ0701the Incubation Project of Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China 2022FH005
6 · The paper itself

Abstract

Vitamin D (VitD) deficiency has been associated with the development of rheumatoid arthritis (RA) and chronic kidney disease (CKD), but its exact role in patients with RA and CKD remains unclear. This cross-sectional study explored the relationship of 25(OH)D2, 25(OH)D3, and Free 25(OH)D [F-25(OH)D] with CKD progression in patients with RA. Patients with RA (n = 1514) were enrolled and divided into the mild, moderate, and severe CKD groups. Total 25(OH)D, 25(OH)D3, and F-25(OH)D in the moderate and severe CKD groups were lower than in the mild CKD group (all P < 0.05), while there were no differences in 25(OH)D2 levels (P = 0.095). As the severity of CKD progressed, total 25(OH)D, 25(OH)D3, and F-25(OH)D decreased (all Padj.<0.05). When progressing from moderate to severe CKD, only 25(OH)D3 decreased significantly (Padj.=0.014). Partial correlation and multiple logistic regression analyses revealed a significant association between 25(OH)D3 and the progression of CKD deterioration, as did F-25(OH)D (all P < 0.05). Further seasonal stratified analysis showed that this correlation existed only in spring, summer, and autumn for 25(OH)D3 and only in spring and summer for F-25(OH)D (P < 0.05). In conclusion, the serum 25(OH)D3 and F-25(OH)D levels may be indicators of CKD progression in patients with RA to plan for timely intervention and management.

Indexed as

Arthritis, RheumatoidCalcifediolRenal Insufficiency, ChronicVitamin DAdultAgedBiomarkersCross-Sectional StudiesDisease ProgressionFemaleHumansMaleMiddle AgedSeverity of Illness IndexVitamin D DeficiencyBiomarkersCalcifediolVitamin D25(OH)D metabolitesChronic kidney diseaseF-25(OH)DRheumatoid arthritis

Identifiers

PMID40281066
PMCPMC12032023

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.